329 related articles for article (PubMed ID: 1967190)
1. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.
Phair J; Muñoz A; Detels R; Kaslow R; Rinaldo C; Saah A
N Engl J Med; 1990 Jan; 322(3):161-5. PubMed ID: 1967190
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
5. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
[TBL] [Abstract][Full Text] [Related]
7. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary study of pneumocystis carinii pneumonia diagnosed by induced expectoration in HIV positive patients in Dakar].
Sow PS; Diouf G; Diop BM; Mboup A; Wangre A; Marlink R; Ndir O; Coll-Seck AM
Dakar Med; 1993; 38(2):115-8. PubMed ID: 7758366
[TBL] [Abstract][Full Text] [Related]
9. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
[TBL] [Abstract][Full Text] [Related]
10. The effects on survival of early treatment of human immunodeficiency virus infection.
Graham NM; Zeger SL; Park LP; Vermund SH; Detels R; Rinaldo CR; Phair JP
N Engl J Med; 1992 Apr; 326(16):1037-42. PubMed ID: 1347907
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
[TBL] [Abstract][Full Text] [Related]
12. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
Hirschtick RE; Glassroth J; Jordan MC; Wilcosky TC; Wallace JM; Kvale PA; Markowitz N; Rosen MJ; Mangura BT; Hopewell PC
N Engl J Med; 1995 Sep; 333(13):845-51. PubMed ID: 7651475
[TBL] [Abstract][Full Text] [Related]
13. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. European Collaborative Study Group.
BMJ; 1994 Feb; 308(6926):437-40. PubMed ID: 7907246
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
[TBL] [Abstract][Full Text] [Related]
15. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
17. [The prevention of Pneumocystis carinii pneumonia by pentamidine inhalation].
Jablonowski H; Elsing C; Erckenbrecht J; Hengels KH; Strohmeyer G
Dtsch Med Wochenschr; 1992 Jul; 117(31-32):1181-4. PubMed ID: 1353721
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
